Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond
Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Frontiers Media SA
2018
|
| Series: | Frontiers Research Topics
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_58773 | ||
| 005 | 20210212 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210212s2018 xx |||||o ||| 0|eng d | ||
| 020 | |a 978-2-88945-539-3 | ||
| 020 | |a 9782889455393 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3389/978-2-88945-539-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MFG |2 bicssc | |
| 100 | 1 | |a Stefano Morotti |4 auth | |
| 700 | 1 | |a Eleonora Grandi |4 auth | |
| 700 | 1 | |a Esther Pueyo |4 auth | |
| 700 | 1 | |a Blanca Rodriguez |4 auth | |
| 245 | 1 | 0 | |a Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond |
| 260 | |b Frontiers Media SA |c 2018 | ||
| 300 | |a 1 electronic resource (385 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Frontiers Research Topics | |
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Physiology |2 bicssc | |
| 653 | |a cardiotoxicity | ||
| 653 | |a cardiac electrophysiology. | ||
| 653 | |a drug-induced arrhythmia | ||
| 653 | |a QT interval prolongation | ||
| 653 | |a multi-scale modeling | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://www.frontiersin.org/research-topics/5662/safety-pharmacology---risk-assessment-qt-interval-prolongation-and-beyond |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/58773 |7 0 |z DOAB: description of the publication |